Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma

Biomarkers

Volumn 18, Issue 8, 2013, Pages 687-698

  Chiu, Tai Jan ^a,b   Chen, Yi Ju ^c   Rau, Kun Ming ^a   Chen, Chang Han ^a   Chien, Chih Yen ^a   Li, Shau Hsuan ^a   Tsai, Hsin Ting ^a   Eng, Hock Liew ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

Author keywords

Chemoradiotherapy; Disease free survival; Head and neck squamous cell carcinoma; Metastasis; Midkine; Prognosis; Survival rate; Tissue array

Indexed keywords

ANTINEOPLASTIC AGENT; MIDKINE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; WESTERN BLOTTING;

BASE SEQUENCE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DNA PRIMERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84889762373     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.846412     Document Type: Article

References (40)

1. AJCC. (2002). Staging manual. 6th ed. New York: Springer-Verlag
2. Al-Sarraf M, Pajak TF, Byhardt RW, et al. (1997). Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37:777-82
3. Aridome K, Takao S, Kaname T, et al. (1998). Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas. Br J Cancer 78:472-7
4. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. (1996). Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 36:999-1004
5. Chaudhary AK, Pandya S, Mehrotra R, et al. (2010). Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers 15:684-92
6. Chaudhary AK, Pandya S, Mehrotra R, et al. (2011). Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers 16:577-86
7. Cortesina G, Martone T. (2006). Molecular metastases markers in head and neck squamous cell carcinoma: Review of the literature. Acta Otorhinolaryngol Ital 26:317-25
8. Elahi M, Rakhshan V, Ghasemian NT, et al. (2012). Prognostic value of transforming growth factor beta 1 [TGF-b1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers 17:21-7
9. Ferlito A, Silver CE, Rinaldo A. (2008). Neck dissection: Present and future? Eur Arch Otorhinolaryngol 265:621-6
10. Forastiere A, Koch W, Trotti A, et al. (2001). Head and neck cancer. N Engl J Med 345:1890-900
11. Garver Jr RI, Radford DM, Donis-Keller H, et al. (1994). Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74:1584-90
12. Ginos MA, Page GP, Michalowicz BS, et al. (2004). Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64:55-63
13. Güngö r C, Zander H, Effenberger KE, et al. (2011). Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 71:5009-19
14. Hu R, Yan Y, Li Q, et al. (2010). Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. Int J Hematol 92:105-10
15. Jemal A, Siegel R, Ward E, et al. (2007). Cancer statistics, 2007. CA Cancer J Clin 57:43-66
16. Jham BC, Costa NL, Silva JM, et al. (2012). Midkine expression in oral squamous cell carcinoma and leukoplakia. J Oral Pathol Med 41:21-6
17. Kadomatsu K, Huang RP, Suganuma T, et al. (1990). A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 110:607-16
18. Kadomatsu K, Tomomura M, Muramatsu T. (1988). cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 151:1312-18
19. Kang HC, Kim IJ, Park JH, et al. (2004). Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-84
20. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. (2007). Serum midkine depends on lymph node involvement and correlates with circulating VEGF-C in oesophageal squamous cell carcinoma. Biomarkers 12:403-13
21. Lentsch EJ. (2004). Management of cervical metastasis. Curr Oncol Rep 6:141-51
22. Mitsuhashi A, Suzuka K, Yamazawa K, et al. (2005). Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 103:724-30
23. Miyauchi M, Shimada H, Kadomatsu K, et al. (1999). Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 90: 469-75
24. Moon HS, Park WI, Sung SH, et al. (2003). Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer. Gynecol Onocol 88:289-97
25. Ota K, Fujimori H, Ueda M, et al. (2008). Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer 99:655-62
26. Ota K, Fujimori H, Ueda M, et al. (2010). Midkine expression is correlated with an adverse prognosis and is down-regulated by p53 in oral squamous cell carcinoma. Int J Oncol 37:797-804
27. Ota T, Jono H, Ota K, et al. (2012). Downregulation of midkine induces cisplatin resistance in human oral squamous cell carcinoma. Oncol Rep 27:1674-80
28. Ota T, Ota K, Jono H, et al. (2010). Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis. Oral Oncol 46:657-61
29. Qi M, Ikematsu S, Ichihara-Tanaka K, et al. (2000). Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: Regulation of Bcl-2 expression by Midkine. J Biochem 127:269-77
30. Ren YJ, Zhang QY. (2006). Expression of midkine and its clinical significance in esophageal squamous cell carcinoma. World J Gastroenterol 12:2006-10
31. Ruan M, Ji T, Wu Z, et al. (2007). Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg 36:159-64
32. Salama RH, Muramatsu H, Zou P, et al. (2006). Midkine, a heparinbinding growth factor, produced by the host enhances metastasis of Lewis lung carcinoma cells. Cancer Lett 233:16-20
33. Sandra F, Harada H, Nakamura N, et al. (2004). Midkine induced growth of ameloblastoma through MAPK and Akt pathways. Oral Oncol 40: 274-80
34. Sato W, Kadomatsu K, Yuzawa Y, et al. (2001). Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 167:3463-9
35. Shimizu S, Tsukada J, Sugimoto T, et al. (2008). Identification of a novel therapeutic target for head and neck squamous cell carcinomas: A role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer 123:1816-23
36. Takei Y, Kadomatsu K, Matsuo S, et al. (2001). Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61:8486-91
37. Takei Y, Kadomatsu K, Yuasa K, et al. (2005). Morpholino antisense oligomer targeting human midkine: Its application for cancer therapy. Int J Cancer 114:490-7
38. Tomomura M, Kadomatsu K, Nakamoto M, et al. (1990). A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. Biochem Biophys Res Commun 171:603-9
39. Xu Y, Qu X, Zhang X, et al. (2009). Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett 279:137-44
40. Yen CY, Huang CY, Hou MF, et al. (2013). Evaluating the performance of fibronectin 1 (FN1), integrin a4b1 (ITGA4), syndecan-2 (SDC2), and glycoprotein CD44 as the potential biomarkers of oral squamous cell carcinoma (OSCC). Biomarkers 18:63-72.